Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $20.83
Previous CloseN/A
Volume136.88K
Average Volume (3M)112.36K
Market Cap
$11.76M
Enterprise Value-$903.51K
Total Cash (Recent Filing)-$437.19K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta5.85
Next Earnings
May 07, 2025EPS Estimate
-1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.79
Shares Outstanding3,212,233
10 Day Avg. Volume100,305
30 Day Avg. Volume112,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.55
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$13.33Price Target Upside264.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc. Advances Towards FDA Approval for CTx-1301
PremiumCompany Announcements
Cingulate Inc Completes Key FDA Study for ADHD Drug
---
Bulls Say, Bears Say
Bulls Say
Market PotentialConsidering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.
Regulatory ApprovalCingulate has completed its final FDA-required clinical program for CTx-1301, which is a significant step towards FDA approval for the treatment of ADHD.
Bears Say
Clinical Study ResultsDespite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.
---
Ownership Overview
63.15% Insiders
0.25% Mutual Funds
0.16% Other Institutional Investors
36.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $1.80 and its highest was $20.83 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $11.76M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is May 07, 2025 which is in 55 days.
How were Cingulate Inc’s earnings last quarter?
Currently, no data Available
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -1.38.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,212,233 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 0.
---
Company Description
Cingulate Inc
Cingulate Inc (CING) is a biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. It operates within the healthcare sector, specifically targeting conditions such as Attention Deficit/Hyperactivity Disorder (ADHD). The company's core products are designed to improve patient outcomes by addressing unmet medical needs through its proprietary drug delivery technology, which aims to optimize the efficacy and safety of therapeutics.
---
CING Stock 12 Month Forecast
Average Price Target
$13.33
▲(264.21% Upside)
Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-59.40%
reiterated a buy rating 10 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.40% per trade.
---